Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.
John William EikelboomJacqueline BoschStuart J ConnollyJessica TyrwittKeith A A FoxEva MuehlhoferChristoph NeumannChristoph TastoShrikant I BangdiwalaRafael DiazMarco AlingsGilles R DagenaisDarryl P LeongEva M LonnAlvaro AvezumLeopoldo Soares PiegasPetr WidimskyAlexander N ParkhomenkoDeepak L BhattKelley R H BranchJeffrey L ProbstfieldPatricio Lopez-JaramilloLars RydénNana PogosovaKatalin KeltaiMatyas KeltaiGeorg ErtlStefan StoerkAntonio L DansFernando Tomás Lanas ZanettiYan LiangJun ZhuChristian Torp-PedersenAldo Pietro MaggioniPatrick J CommerfordTomasz J GuzikThomas VanasschePeter VerhammeMartin O'DonnellAndrew M TonkinJohn D VarigosDragos VinereanuCamillo FelixJae-Hyung KimKhairul S IbrahimBasil S LewisKaj P MetsarinneVictor AboyansPhillippe Gabriel StegMasatsugu HoriAjay KakkarSonia S AnandAndre LamyMukul SharmaSalim YusufPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
In patients with chronic CAD and/or PAD, extended combination treatment for a median of 1 year and a maximum of 3 years was associated with incidence rates for efficacy and bleeding that were similar to or lower than those seen during the randomized treatment phase, without any new safety signals.
Keyphrases
- open label
- phase iii
- clinical trial
- coronary artery disease
- phase ii
- peripheral artery disease
- randomized controlled trial
- type diabetes
- combination therapy
- study protocol
- double blind
- venous thromboembolism
- heart failure
- risk factors
- cardiovascular events
- metabolic syndrome
- insulin resistance
- percutaneous coronary intervention
- placebo controlled
- phase ii study
- rectal cancer
- ejection fraction